Johnson & Johnson wants other people’s drugs.
The world’s largest health care company has an open-door policy when it comes to partnering with other drug makers, and it’s Dr. William Hait’s job to make sure J&J gets a crack at the best new ideas in the industry.
Hait, J&J’s head of external innovation, said that about 50 percent of the company’s current pipeline is made up of projects licensed from other drug makers. That’s no accident, Hait said, as J&J has spent years distancing itself from the solipsistic old pharma model, using a little scientific humility and a lot of cash to establish a sweeping network of partners across the industry.
About the Author Reprints
